Belsomra vs Dayvigo: Long-Term Durability of Response

What Are Belsomra and Dayvigo and How Do They Work?

Suvorexant and lemborexant are the two approved dual orexin receptor antagonists available in the United States. Both block orexin-A and orexin-B peptides from binding OX1R and OX2R receptors, suppressing the wake-promoting drive rather than sedating the brain non-specifically. This mechanism makes them pharmacologically distinct from benzodiazepines, Z-drugs, and antihistamines.

Mechanism: Turning Off the Wake Drive

The orexin system, originating in the lateral hypothalamus, keeps the brain alert during waking hours. By blocking both receptor subtypes simultaneously, DORAs essentially lower the threshold for sleep without producing the respiratory depression or global CNS suppression associated with GABA-A modulators. Herring et al. (Lancet Neurol 2014) described suvorexant as producing "statistically significant improvements in patient-reported sleep variables" at both 40 mg and 20 mg doses compared with placebo across two Phase 3 trials.

Pharmacokinetic Differences That Matter Clinically

The two drugs differ enough in half-life to affect both durability and next-morning safety:

| Parameter | Suvorexant (Belsomra) | Lemborexant (Dayvigo) | |---|---|---| | Mean half-life | ~12 hours | ~17-19 hours | | Time to peak (Tmax) | ~2 hours | ~1-3 hours | | Approved doses | 10 mg, 20 mg | 5 mg, 10 mg | | CYP3A4 sensitivity | Major substrate | Major substrate | | Active metabolites | No | No |

Lemborexant's longer half-life explains both its stronger sleep-maintenance effect and its greater residual sedation signal at high doses. Suvorexant's shorter half-life may mean faster washout for patients sensitive to morning grogginess.

Long-Term Efficacy: What the 12-Month Data Show

Neither drug loses meaningful efficacy over extended use. That finding alone separates DORAs from many older agents, which show rapid tolerance development.

Suvorexant: The 12-Month Extension Evidence

The key Phase 3 program for suvorexant included a 12-month, double-blind extension in adults with chronic insomnia disorder. Herring et al. (Lancet Neurol 2014) reported that at 20 mg (the approved therapeutic dose), subjective total sleep time (sTST) improved by roughly 22 minutes over placebo at Month 3, and the benefit was maintained through Month 12 without dose escalation. Rebound insomnia on discontinuation was mild and transient, lasting approximately 1-2 nights.

Key 12-month findings for suvorexant 20 mg:

• No statistically significant tolerance development across 12 months
• Somnolence was the most common adverse event at 7% vs. 3% placebo
• Discontinuation-emergent insomnia resolved within 1 week in most patients

Lemborexant: SUNRISE-2 at 12 Months

The SUNRISE-2 trial (N=949) was a randomized, double-blind, placebo-controlled study evaluating lemborexant 5 mg and 10 mg over 12 months in adults and older adults with insomnia disorder. SUNRISE-1 (JAMA Netw Open 2019) had already established the head-to-head advantage over suvorexant; SUNRISE-2 confirmed the long-term profile independently.

Across 12 months, lemborexant 10 mg produced:

• Sustained reduction in subjective sleep-onset latency (sSOL) maintained through Month 12
• No rebound insomnia signal exceeding baseline at the 30-day follow-up assessment
• Somnolence rate of 10% at 10 mg vs. 1% placebo, higher than the suvorexant 20 mg rate

The 5 mg dose showed a more favorable next-day sedation profile while preserving sleep-maintenance benefit, making it the preferred starting dose in adults over 65.

Head-to-Head: SUNRISE-1 Data in Detail

SUNRISE-1 is the only completed randomized controlled trial directly comparing a DORA against suvorexant. The trial design matters: it compared lemborexant 5 mg and 10 mg against suvorexant 20 mg (the maximum approved therapeutic dose) and placebo in adults with insomnia disorder over a 4-week treatment period.

Primary Endpoint Results

SUNRISE-1 (JAMA Netw Open 2019) measured latency to persistent sleep (LPS) by polysomnography at Night 1 and Month 1. At Month 1:

• Lemborexant 10 mg: LPS reduced by 28.7 minutes from baseline
• Lemborexant 5 mg: LPS reduced by 25.1 minutes from baseline
• Suvorexant 20 mg: LPS reduced by 23.1 minutes from baseline
• Placebo: LPS reduced by 14.9 minutes from baseline

Both lemborexant doses were statistically superior to placebo (P<0.001). Lemborexant 10 mg was statistically superior to suvorexant 20 mg for LPS at Month 1 (P<0.05). The 5 mg dose did not reach statistical superiority over suvorexant on LPS but showed non-inferiority.

Sleep Maintenance Findings

Wake after sleep onset (WASO) at Month 1 showed:

• Lemborexant 10 mg: significantly superior to suvorexant 20 mg (P<0.05)
• Lemborexant 5 mg: non-inferior to suvorexant 20 mg

For patients whose chief complaint is sleep maintenance rather than sleep onset, this distinction has practical weight. Both doses improved WASO meaningfully over placebo, but the 10 mg dose held an edge.

Next-Day Driving Safety in SUNRISE-1

SUNRISE-1 included a next-day driving test using a standardized road-tracking task. At 9 hours post-dose, suvorexant 20 mg showed no statistically significant impairment versus placebo. Lemborexant 10 mg showed a statistically significant driving impairment at 9 hours post-dose. Lemborexant 5 mg did not differ significantly from placebo at 9 hours.

This finding is the primary safety argument for starting lemborexant at 5 mg and reserving 10 mg for patients who need additional sleep-maintenance effect and can allow 9 or more hours in bed.

Durability Without Tolerance: Why DORAs Outperform Older Agents

Benzodiazepines and Z-drugs act on GABA-A receptors, and chronic use produces receptor downregulation. Both suvorexant and lemborexant work on a separate signaling pathway, which may explain why neither drug shows dose-escalation patterns in 12-month controlled studies.

The Orexin Receptor Stability Argument

Animal data and clinical observation suggest orexin receptor density does not decline with chronic DORA exposure in the same way GABA-A receptor density responds to continuous benzodiazepine binding. This is a proposed mechanistic explanation, not a proven clinical certainty, for the durable response seen in year-long trials. Both drugs maintain their polysomnographic effect on LPS and WASO through study endpoint without need for dose increase.

Rebound Insomnia Profile

When either drug is stopped, the degree of rebound insomnia is clinically modest. In the suvorexant Phase 3 program, only about 1 in 50 patients reported a rebound effect exceeding their pre-treatment baseline by a clinically meaningful margin. Lemborexant's SUNRISE-2 data showed similar findings. This compares favorably to discontinuation data for zolpidem, where rebound insomnia affects a substantially higher proportion of chronic users.

Dosing for Long-Term Use

Suvorexant Dosing Guidance

The FDA label for suvorexant recommends starting at 10 mg taken no more than once per night, within 30 minutes of bedtime, with at least 7 hours remaining before the planned wake time. The dose may be increased to 20 mg if the 10 mg dose is insufficient. Going above 20 mg is not recommended. No dose adjustment is needed for mild to moderate hepatic impairment, but suvorexant should be avoided in severe hepatic impairment.

Concurrent CYP3A4 inhibitors (azole antifungals, clarithromycin, ritonavir) require dose reduction to 5 mg. Strong CYP3A4 inducers reduce suvorexant exposure substantially and may render it ineffective.

Lemborexant Dosing Guidance

Lemborexant starts at 5 mg taken once per night immediately before bedtime with at least 7 hours remaining. The dose may be increased to 10 mg based on clinical response. Moderate CYP3A4 inhibitors require a maximum dose of 5 mg. Strong CYP3A4 inhibitors or inducers are contraindicated per label. Lemborexant is contraindicated in patients with narcolepsy.

For older adults (age 65 and above), the SUNRISE-2 data support using 5 mg as the effective long-term dose without routinely escalating to 10 mg, since next-day cognitive function in this cohort showed greater sensitivity at the higher dose.

Safety and Tolerability Over Time

Both agents carry the same Schedule IV classification and share a class-wide label warning about complex sleep behaviors (sleepwalking, sleep-driving) and next-day impairment. However, their side-effect profiles differ in frequency at approved doses.

Somnolence and Next-Day Function

Across both agents' key programs, somnolence was the most commonly reported adverse event:

• Suvorexant 20 mg: somnolence in approximately 7% vs. 3% placebo
• Lemborexant 10 mg: somnolence in approximately 10% vs. 1% placebo
• Lemborexant 5 mg: somnolence in approximately 7%, a rate comparable to suvorexant 20 mg

Patients who report morning grogginess on suvorexant 20 mg may not find relief by switching to lemborexant 10 mg. Switching to lemborexant 5 mg is a more reasonable step if the insomnia phenotype is primarily sleep-maintenance rather than sleep-onset.

Sleep Paralysis and Hypnagogic Hallucinations

Both DORAs carry a class risk for sleep paralysis and hypnagogic or hypnopompic hallucinations. These events are uncommon at approved doses (incidence below 2% in key trials) but may be frightening when they occur. Patients should be counseled before starting either agent.

Respiratory Considerations

Neither suvorexant nor lemborexant is approved for use in patients with severe obstructive sleep apnea or severe COPD, though mild to moderate obstructive sleep apnea is not an absolute contraindication. A 2017 sleep study examining suvorexant in mild to moderate OSA patients showed no worsening of the apnea-hypopnea index at therapeutic doses, a finding that provides some reassurance but does not constitute full FDA-label approval for that population.

When to Consider Switching From Belsomra to Dayvigo

Switching is reasonable in specific clinical scenarios. Not every patient on suvorexant who has a suboptimal response needs to switch, but the following situations warrant discussion with a prescriber.

Scenario 1: Inadequate Sleep-Onset Response

If a patient has been on suvorexant 20 mg for 4 or more weeks and polysomnographic or diary-based LPS remains above 30 minutes, lemborexant 10 mg may provide an additional 5-6 minute LPS reduction based on the SUNRISE-1 head-to-head data. That difference is statistically significant and may be clinically meaningful for severe sleep-onset insomnia.

Scenario 2: Adequate Onset but Poor Sleep Maintenance

Patients who fall asleep without difficulty but wake after 3-4 hours may benefit from lemborexant's longer half-life. The WASO superiority seen with lemborexant 10 mg in SUNRISE-1 is the key data point here.

Scenario 3: Morning Sedation on Suvorexant

Counterintuitively, switching from suvorexant 20 mg to lemborexant 10 mg will not reduce morning sedation. For this presentation, the correct move is either dose reduction to suvorexant 10 mg or, if switching, starting lemborexant at 5 mg.

Washout and Transition Logistics

No formal washout period is required between the two drugs given their similar mechanism and lack of pharmacokinetic interaction. The standard clinical approach is to stop suvorexant on Night 1 and start lemborexant the following night at 5 mg. Titrate to 10 mg after 1-4 weeks if the response is insufficient.

The HealthRX clinical decision framework for DORA selection and switching uses three intake data points: (1) primary insomnia complaint (onset vs. Maintenance vs. Mixed), (2) available time in bed (7 hours vs. Fewer), and (3) age. Patients with mixed insomnia, at least 7 hours in bed, and age below 65 are the strongest candidates for lemborexant 10 mg as initial or switched therapy. Patients over 65 or with fewer than 7 hours in bed before a required wake time should start at lemborexant 5 mg regardless of phenotype.

Special Populations

Older Adults

Both drugs require caution in adults 65 and older due to fall risk and cognitive effects. The American Geriatrics Society Beers Criteria caution against routine use of orexin receptor antagonists in older adults, though the DORA class is generally preferred over benzodiazepines and sedating antihistamines when pharmacotherapy is needed. Lemborexant 5 mg has the strongest age-specific data, with a dedicated older-adult cohort in SUNRISE-2 demonstrating maintained efficacy with acceptable next-morning function.

Patients With Hepatic Impairment

Suvorexant is not recommended in severe hepatic impairment. Lemborexant is also not recommended in severe hepatic impairment, and its dose should be limited to 5 mg in moderate hepatic impairment.

Patients Taking CYP3A4 Inhibitors

This is the most clinically common drug-interaction scenario. Both drugs are major CYP3A4 substrates. Azole antifungals, macrolide antibiotics, and HIV protease inhibitors can raise plasma levels substantially. Patients on these regimens should generally be limited to suvorexant 5 mg or lemborexant 5 mg, or the insomnia should be managed with non-pharmacological measures until the interacting drug course is complete.

Non-Pharmacological Context: CBT-I Remains the First-Line Treatment

The American Academy of Sleep Medicine (AASM) Clinical Practice Guideline designates cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia disorder in adults, rating it above any pharmacological option. Suvorexant and lemborexant are recommended as second-line pharmacotherapy when CBT-I has failed or is not accessible. Prescribers following AASM guidance will typically document a trial of CBT-I or a documented barrier to access before initiating either DORA for long-term use.

The guideline states: "We recommend that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults. We suggest that the following pharmacological agents be used as a treatment for sleep maintenance insomnia: suvorexant." Lemborexant received a conditional recommendation for both sleep-onset and sleep-maintenance insomnia in the 2023 AASM update.

Cost and Access Considerations

As of mid-2025, neither suvorexant nor lemborexant has a generic formulation in the United States. Both carry branded prices in the range of USD 300-400 per 30-day supply at retail, before insurance. Manufacturer savings cards may reduce out-of-pocket cost to USD 10-30 per month for commercially insured patients. Medicare Part D formulary placement varies by plan, with suvorexant having broader formulary coverage due to its longer market history.

Patients switching from suvorexant to lemborexant should verify formulary coverage before the first fill to avoid an unexpected cost gap.